Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/regenxbio-announces-lancet-publication-of-phase-iiia-study-evaluating-abbv-rgx-314-as-a-one-time-gene-therapy-for-wet-amd-302102175.html
https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-participate-cantor-fitzgeralds-virtual-dmd-and-other
https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-participate-upcoming-investor-conferences-17
https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-announces-pricing-upsized-public-offering-common-stock
https://www.prnewswire.com/news-releases/regenxbio-announces-proposed-public-offering-of-common-stock-302082085.html
https://www.prnewswire.com/news-releases/regenxbio-announces-new-positive-initial-efficacy-data-from-affinity-duchenne-trial-302079525.html
https://www.pharmaceutical-technology.com/projects/regenxbio-research-and-development-facility-maryland/
https://www.prnewswire.com/news-releases/regenxbio-to-host-webcast-event-to-discuss-new-interim-clinical-data-from-the-phase-iii-affinity-duchenne-trial-302076483.html
https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-host-webcast-event-discuss-new-interim-clinical-data
https://www.prnewswire.com/news-releases/regenxbio-reports-fourth-quarter-and-full-year-2023-financial-results-and-recent-operational-highlights-302073278.html